News & Events

Learn about what's new with CMC Biologics

AdaptVac Partners with AGC Biologics to Develop & Produce COVID-19 Vaccine

News

(SEATTLE), April 23, 2020 -- AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it is partnering with AdaptVac to develop and produce a COVID-19 vaccine. AdaptVac, together with its EU Horizon 2020 sponsored PREVENT-nCoV consortium partners, are developing a SARS-CoV-2 vaccine. The COVID-19 pandemic is still evolving, and AdaptVac’s Virus-Like Particle (VLP) technology could provide a solution to protect against new SARS-CoV-2 infections.

AGC Biologics to Participate in Virtual BIO-Europe Spring

News

AGC Biologics Sponsors 14th Annual BIO-Europe Spring Conference

AGC Biologics in the news for our work toward COVID-19 treatment

News

Seattle CBS affiliate KIRO visited our Bothell, Washington headquarters to interview AGC Biologics CEO Patricio Massera and Chief Business Officer Mark Womack about the work we’re doing with partner CytoDyn. CytoDyn scientists discovered that HIV drug leronlimab could potentially work to treat COVID-19. AGC Biologics is producing a key molecule for the drug.

DCAT Week Cancelled, AGC Biologics to Meet Virtually with Industry Leaders

News

AGC Biologics fosters strong customer partnerships by conducting virtual meetings

AGC Inc. Decides to Launch Voluntary Tender Offer for Shares of Molmed

News

Tokyo, March 17, 2020 – AGC Inc., (Headquarters: Tokyo; President & CEO: Takuya Shimamura) has decided to launch a voluntary tender offer (“VTO”) to acquire all ordinary shares of Molecular Medicine S.p.A. (“Molmed”) a company with shares listed on the Italian Stock Exchange (Milan) pursuant to article 102, first paragraph, of the Italy Legislative Decree No. 58 of 24 February 1998 and related regulations. Molmed is a clinical stage biotechnology company focused on research, development, manufacturing and clinical validation of gene & cell therapies, and offers GMP services for the development and manufacturing of gene & cell therapies for third parties and/or in partnership at its authorized facilities (“CDMO Services”*1).

AGC Biologics Plasmid Production

News

 

Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseases

News

AGC Biologics Expands Plasmid DNA Offering

News

SEATTLE, December 11, 2019-- AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, is significantly expanding its CDMO services with plasmid DNA (pDNA) offerings from its Heidelberg site in Germany. With the demand for pDNA growing rapidly, AGC Biologics is leveraging 25 years of experience and comprehensive in-house analytics development to ensure customers short and dependable timelines.

AGC Biologics’ $18m Investment in Seattle and Denmark Facilities Strengthens Global Footprint

News

SEATTLE, WA -- November 11th, 2019 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that their development and manufacturing capabilities at their Seattle, Washington and Copenhagen, Denmark facilities will be expanded, as part of an ongoing commitment to deliver the highest standard of service for their customers.

AGC Biologics Appoints New Site Head/General Manager  of Copenhagen, Denmark Operations

News

Jeffrey D. Mowery Named Site Head/General Manager

Follow Us
Join us on LinkedIn Follow us on Twitter